Source: Nuvilex, Inc – Press Release March 25, 2014
Dr. Mark L. Rabe to Speak on “Unique Applications for Cannabinoid Chemotherapy Therapy”
SILVER SPRING, Md., March 25, 2014 (GLOBE NEWSWIRE) — Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that holistic and medical marijuana expert Dr. Mark L. Rabe, Chairman of the Scientific Advisory Board of Nuvilex’s subsidiary, Medical Marijuana Sciences, Inc., will deliver a significant presentation at the 2nd Annual National Medical Cannabis Unity Conference “Navigating Medical Cannabis in the Mainstream” that will be held in Washington, DC April 5-7, 2014. Dr. Rabe’s presentation will take place at the Mayflower Hotel on April 6.
Dr. Rabe will review the history of the use of marijuana and its constituents for medicinal purposes and discuss the constituents of the marijuana plant, known as cannabinoids, which have historically shown biological activity, with particular emphasis on their use in treating serious and deadly diseases. Most importantly, Dr. Rabe will speak to the potential use of cannabinoids in combination with the proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box® in developing treatments for pancreatic and brain cancer, two of the deadliest forms of that disease. Cell-in-a-Box®, in combination with the anticancer drug ifosfamide, was proven effective in early-stage clinical trials and is currently being prepared for late-stage clinical trials by Nuvilex for the treatment of advanced, inoperable pancreatic cancer.
The National Medical Cannabis Unity Conference is sponsored by Americans for Safe Access (ASA). The goals of the ASA are to ensure safe and legal access to marijuana (cannabis) for therapeutic uses and research. The Conference will allow patients, medical practitioners and advocates of medical marijuana to interact, exchange ideas and discuss the navigation of medical marijuana in today’s political landscape.
Kenneth L. Waggoner, CEO and President of Nuvilex, commented, “The presentation by Dr. Rabe at this important conference will help showcase Medical Marijuana Sciences and its efforts to develop cannabis-based cancer treatments to a diverse community of those with a genuine interest in developing constituents of marijuana for medical treatment of serious diseases and their associated symptoms. It is our hope that, through events such as the National Medical Cannabis Unity Conference, the usefulness of constituents of cannabis for serious and deadly diseases can ultimately be fully realized.”
Nuvilex is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and diabetes are being built. Nuvilex’s treatment for pancreatic cancer involves the widely used anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form. Nuvilex is also involved in clinical trials related to other aspects of pancreatic and other forms of cancer. Nuvilex’s subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon chemical constituents of marijuana known as cannabinoids. To do so, it will examine ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids against cancers while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides Medical Marijuana Sciences a unique opportunity to develop “green” approaches to fighting deadly cancers, such as those of the pancreas, brain, breast and prostate, that affect hundreds of thousands of individuals worldwide every year.
This press release may contain forward-looking statements regarding Nuvilex and its future events and results that involve inherent risks and uncertainties. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to Nuvilex or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of Nuvilex, that could cause actual results to differ materially from those set forth in the forward-looking statements include Nuvilex’s ability to continue as a going concern, delays in clinical trials or flaws or defects regarding its products, changes in relevant legislation or regulatory requirements, uncertainty of protection of Nuvilex’s intellectual property and Nuvilex’s continued ability to raise capital. Nuvilex does not assume any obligation to update any of these forward-looking statements.
CONTACT: Investor Relations Contacts: Marlin Molinaro Marmel Communications, LLC Telephone: 702.434.8692 [email protected] Dillon Heins CorProminence, LLC Telephone: 218.839.9051 [email protected]